Applied Genetic Technologies Corporation (AGTC) News

Applied Genetic Technologies Corporation (AGTC): $0.28

-0.01 (-4.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGTC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 403

in industry

Filter AGTC News Items

AGTC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGTC News Highlights

  • AGTC's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for AGTC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about AGTC are GENE, PDS and RARE.

Latest AGTC News From Around the Web

Below are the latest news stories about APPLIED GENETIC TECHNOLOGIES CORP that investors may wish to consider to help them evaluate AGTC as an investment opportunity.

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor confe

Yahoo | September 1, 2022

H.C. Wainwright Keeps Their Buy Rating on Applied Genetic Technologies (AGTC)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTC - Research Report), with a price target of $24.00. The company's shares closed yesterday at $0.44.Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -15.7% and a 33.77% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Applied Genetic Technologies with a $24.00 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $3.

Howard Kim on TipRanks | August 18, 2022

AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility

— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the late-stage development and potential commercialization of AGTC’s X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs — GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of a

Yahoo | July 26, 2022

6 Penny Stocks With 1,000% Upside Potential

Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny stocks with 1,000% upside potential. That would be a return any investor would love. First, the methodology for assessing upside potential: This is simply a measure of the current price against the target price. So, all of these stocks above could turn $1,000 into $11,000 is ana

Yahoo | July 24, 2022

AGTC Announces Pricing of $10 Million Underwritten Public Offering

GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 1

Yahoo | July 13, 2022

AGTC Announces Proposed Underwritten Public Offering

GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it intends to offer and sell in an underwritten public offering, subj

Yahoo | July 12, 2022

AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting

July 7, 2022 at 8:00 AM EDTGAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced two encore presentations on the interim safety results in three studies. One of the presentations wil

Yahoo | July 7, 2022

AGTC Announces Key Appointments to Leadership Team

AGTC Welcomes Eduardo Jacobo as the Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as the Sr. Vice President of Clinical Research and Medical AffairsGAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited

Yahoo | June 8, 2022

AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based

Yahoo | June 6, 2022

AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the formation of a scientific advisory board (SAB) comprised of leading experts in age-related macular degeneration (AMD). The S

Yahoo | June 1, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6047 seconds.